OPUS GENETICS INC(IRD)

3.46+0.05+1.32%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- TD Cowen Initiates Opus Genetics at Buy
  MT Newswires Live · 07-29 19:45
  TD Cowen Initiates Opus Genetics at Buy
- Opus Genetics Inc : TD Cowen Initiates Coverage with Buy Rating
  THOMSON REUTERS · 07-29 17:37
  Opus Genetics Inc : TD Cowen Initiates Coverage with Buy Rating
- Opus Genetics initiated with a Buy at TD Cowen
  TIPRANKS · 07-29 17:35
  Opus Genetics initiated with a Buy at TD Cowen
- Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)
  TIPRANKS · 07-10
  Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)
- Opus Genetics sets September timeline for retinal disease trial data
  TIPRANKS · 07-09
  Opus Genetics sets September timeline for retinal disease trial data
- Opus Genetics - to Announce Opgx-best1 Three-month Topline Data from Cohort 1 in September 2026
  THOMSON REUTERS · 07-09
  Opus Genetics - to Announce Opgx-best1 Three-month Topline Data from Cohort 1 in September 2026
- Analysts Are Bullish on Top Healthcare Stocks: Tenet Healthcare (THC), Opus Genetics (IRD)
  TIPRANKS · 07-08
  Analysts Are Bullish on Top Healthcare Stocks: Tenet Healthcare (THC), Opus Genetics (IRD)
- Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)
  TIPRANKS · 07-07
  Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)
- Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target
  TIPRANKS · 07-07
  Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target
- Opus Genetics Price Target Maintained with a $12.00/share by BTIG
  Dow Jones · 07-07
  Opus Genetics Price Target Maintained with a $12.00/share by BTIG
- Opus Genetics FDA alignment further de-risks path to market, says Chardan
  TIPRANKS · 07-06
  Opus Genetics FDA alignment further de-risks path to market, says Chardan
- Opus Genetics Posts Press Release on FDA Alignment for Opgx-lca5 Phase 3 Trial Design
  Reuters · 07-06
  Opus Genetics Posts Press Release on FDA Alignment for Opgx-lca5 Phase 3 Trial Design
- Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for Opgx-lca5 in Lca5-associated Inherited Retinal Disease
  THOMSON REUTERS · 07-06
  Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for Opgx-lca5 in Lca5-associated Inherited Retinal Disease
- Opus Genetics - FDA Allows Bla Submission Based on 6-month Efficacy Data for Opgx-lca5
  THOMSON REUTERS · 07-06
  Opus Genetics - FDA Allows Bla Submission Based on 6-month Efficacy Data for Opgx-lca5
- Opus Genetics - to Initiate Phase 3 Dosing in Q4 2026
  THOMSON REUTERS · 07-06
  Opus Genetics - to Initiate Phase 3 Dosing in Q4 2026
- Opus Genetics Shares Rise on Addition to Russell Indexes
  Dow Jones · 06-26
  Opus Genetics Shares Rise on Addition to Russell Indexes
- Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
  THOMSON REUTERS · 06-26
  Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
- JonesTrading Sticks to Their Buy Rating for Opus Genetics (IRD)
  TIPRANKS · 06-25
  JonesTrading Sticks to Their Buy Rating for Opus Genetics (IRD)
- Opus Genetics Inc : RBC Initiates Coverage With Outperform Rating; Price Target $10
  THOMSON REUTERS · 06-23
  Opus Genetics Inc : RBC Initiates Coverage With Outperform Rating; Price Target $10
- Opus Genetics Is Maintained at Buy by Chardan Capital
  Dow Jones · 06-19
  Opus Genetics Is Maintained at Buy by Chardan Capital
Company Profile
Company Name
OPUS GENETICS INC
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.ocuphire.com;ir.opusgtx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 06-16
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-16
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-15
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 05-13
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-13
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 05-12
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 05-12
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

Loading ...

High

3.54

Open

3.45

Volume%

0.86

Low

3.29

3.41

T/O Rate

1.06%

To The Moon

OPUS GENETICS INC(IRD)

Company Profile

Most Discussed